FDA Approves JAKAFI XR — Incyte Corporation

# FDA Approves Incyte's JAKAFI XR Extended-Release Formulation Incyte Corporation received FDA approval for JAKAFI XR (ruxolitinib), an extended-release oral formulation of its flagship JAK inhibitor, potentially strengthening the company's competitive position in the myeloproliferative neoplasm market by offering improved dosing convenience and patient compliance compared to the original twice-daily regimen. The approval could expand JAKAFI's addressable patient population and drive incremental revenue growth for Incyte, though market uptake will depend on payer coverage and competitive